Lv3
272 积分 2025-09-11 加入
Relationship between [18F]PSMA-1007 PET parameters and biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment
2天前
已完结
Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group
2天前
已完结
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial
2天前
已完结
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
2天前
已完结
Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO)
2天前
已完结
Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients
2天前
已完结
Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial
2天前
已完结
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
2天前
已完结
Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
2天前
已完结
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
4天前
已完结
皖公网安备34019202002308
